BRIDGEBIO: STUDY SHOWS 42% CUT IN TOTAL NUMBER OF ACM AND RECURRENT CVH EVENTS PER PATIENT OBSERVED OVER 30-MTHS WITH ACORAMIDIS TREATMENT VS PLACEBO

Reuters · 09/27 22:00
BRIDGEBIO: STUDY SHOWS 42% CUT IN TOTAL NUMBER OF ACM AND RECURRENT CVH EVENTS PER PATIENT OBSERVED OVER 30-MTHS WITH ACORAMIDIS TREATMENT VS PLACEBO